1. In Vivo

Norway’s Pre Diagnostics Has Alzheimer’s Test In Its Sights

 
• By Ashley Yeo

Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.

[Pre Diagnostics AS] is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.

With an estimated 75 million people having the disease worldwide, Alzheimer’s is the largest untapped market. “We just need a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.